Asparaginase erwinia chrysanthemi (recombinant)-rywn) has been approved as part of the treatment for acute lymphoblastic leukemia for patients who have developed hypersensitivity to E. coli-derived asparaginase, which was approved in 1978. Here, ASPG is linked to acute lymphoblastic leukemia.